Back to search

Article

Timolol reports for infantile hemangioma contain systemic beta- blocker signals in FAERS/openFDA

2026-08-20

Abstract excerpt

<title>Abstract</title> <p>Topical timolol is widely used for selected superficial infantile hemangiomas, but systemic beta-blocker effects remain biologically plausible in young infants. We analyzed FDA Adverse Event Reporting System reports accessed through openFDA to characterize beta-blocker reports with infantile hemangioma indications and to evaluate timolol in context. The downloaded beta-blocker/infantile...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ef657900-306e-5761-8e65-b9524f952348
DOI
10.21203/rs.3.rs-10302806/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Timolol reports for infantile hemangioma contain systemic beta- blocker signals in FAERS/openFDADOI 10.21203/rs.3.rs-10302806/v1
Select a neighboring publication to make it the new centre.